Yorktown Management & Research Company’s Neurocrine Biosciences NBIX Stock Holding History

Yorktown Management & Research Company’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$632K	Buy	3,750 +1,500	+67%	+$223K	0.39%	90
2026 Q1	$296K	Hold	2,250	–	–	0.25%	160
2025 Q4	$319K	Hold	2,250	–	–	0.26%	163
2025 Q3	$316K	Buy	+2,250	New	+$305K	0.25%	165
2025 Q2	–	Sell	-2,850	Closed	-$315K	–	230
2025 Q1	$315K	Hold	2,850	–	–	0.34%	136
2024 Q4	$389K	Hold	2,850	–	–	0.37%	124
2024 Q3	$328K	Buy	+2,850	New	+$391K	0.34%	155
2021 Q2	–	Sell	-2,500	Closed	-$243K	–	256
2021 Q1	$243K	Hold	2,500	–	–	0.2%	197
2020 Q4	$240K	Hold	2,500	–	–	0.22%	206
2020 Q3	$240K	Hold	2,500	–	–	0.22%	229
2020 Q2	$305K	Buy	+2,500	New	+$276K	0.27%	183

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Yorktown Management & Research Company's NBIX Position: Q2 2026 in Review

Yorktown Management & Research Company increased its Neurocrine Biosciences (NBIX) stake by 67% in Q2 2026, buying an estimated $223K and bringing the position to 3,750 shares worth $632K. The position accounts for 0.39% of the portfolio, ranked #90.

Yorktown Management & Research Company first reported a position in NBIX in Q2 2020 and has held it in 11 quarters since. 427 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Yorktown Management & Research Company held 3,750 shares of Neurocrine Biosciences worth $632K as of Q2 2026.
Yorktown Management & Research Company bought 1,500 Neurocrine Biosciences shares in Q2 2026, an estimated $223K.
Neurocrine Biosciences made up 0.39% of Yorktown Management & Research Company's portfolio in Q2 2026, its #90 holding.
Yorktown Management & Research Company first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 11 quarters since.
427 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.